Categories AlphaGraphs, Earnings, Health Care
MRK Earnings: Highlights of Merck’s Q4 2023 financial results
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp fall in adjusted earnings for the fourth quarter of 2023, despite a modest increase in revenues.
Fourth-quarter worldwide sales increased 6% year-over-year to $14.6 billion, mainly reflecting the sustained growth across oncology and vaccines.
The company reported a net loss of $1.23 billion or $0.48 per share for the December quarter, compared to a profit of $3.02 billion or $1.18 per share in the prior-year period. On an adjusted basis, it was earnings of $0.03 per share in Q4, down 98% from the fourth quarter of 2022.
“As we move forward, I’m confident that our strong momentum will continue, underpinned by the unwavering dedication of our talented global team,” said Merck’s CEO Robert Davis.
Prior Performance
Most Popular
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported worldwide net revenues of $13.3 billion for the
Colgate-Palmolive (CL) Q1 2025 Earnings: Key financials and quarterly highlights
Colgate-Palmolive Company (NYSE: CL) reported its first quarter 2025 earnings results today. Net sales decreased 3.1% year-over-year to $4.9 billion. Organic sales growth was 1.4%. Net income attributable to Colgate-Palmolive Company rose
Meta Platforms (META) set to report Q1 earnings. Here’s what to expect
After integrating artificial intelligence into its products, Meta Platforms, Inc. (NASDAQ: META) is investing heavily in the metaverse project. Yet, the tech giant has maintained healthy cash flows and consistently
